Nain Biotech

NAIN Biotech develops small-molecule compounds with novel MOA to overcome cancer recurrence and metastasis. Our pre-clinical leading asset NAI003, a potential FIC PPI modulator targeting PIDA6/IRE1 has superior anticancer potency in serveral PDX models and desirable safety and PK profiles looking for out-licensing partners.

Address

Hangzhou
Zhejiang
China
Loading